Literature DB >> 11815282

A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.

Shi-Fa Ding1, Rocco Lombardi, Reza Nazari, Sadhna Joshi.   

Abstract

Oncoretroviral vectors were engineered to allow constitutive expression of an antisense RNA and the trans-activator of transcription (Tat)-inducible expression of a mRNA containing the trans-activation response (TAR) element, the Rev response element (RRE), and the efficient packaging signal (Psi(e) of human immunodeficiency virus-1 (HIV-1) RNA. Nuclear export of this mRNA by the regulator of expression of virion proteins (Rev) would allow its translation into wild type (WT) (MoTN-Ti-GE-Ri- Ter) or trans-dominant negative mutant (TDM) (MoTN-Ti-GmEm-Ri-Ter) Gag and Env proteins. Thus, the antisense RNA produced in a constitutive manner would ensure that even if there is leaky expression, no WT/TDM Gag or Env protein would be produced in the uninfected cells. If cells become infected by HIV-1, the antisense RNA would inhibit HIV-1 replication. Failure on the part of antisense RNA to inhibit virus replication would allow GE/GmEm mRNA production. The GE/GmEm mRNA would cause partial inhibition of HIV-1 replication as it contains the TAR, RRE, and Psi(e) signal sequences. Translation of GmEm mRNA would give rise to TDM Gag and Env proteins, which would further decrease progeny virus infectivity. Tat- and Rev-inducibility was demonstrated in transfected HeLa and HeLa-Tev cells. Full-length WT/TDM Gag production was confirmed by Western blot analysis. Amphotropic vector particles were used to transduce a human CD4+ T-lymphoid cell line, and the stable transductants were challenged with HIV-1. Virus replication was better inhibited by the MoTN-Ti-GE-Ri-Ter vector than by the MoTN-Ti-GmEm-Ri-Ter vector. Inhibition of HIV-1 replication was also demonstrated in transduced CD4+ human peripheral blood T lymphocytes (PBLs). Moreover, our results suggest that cloning in the reverse transcriptional orientation must be avoided to prevent antisense RNA-mediated inhibition of transgene and endogenous gene expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815282     DOI: 10.2741/ding

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

1.  Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.

Authors:  Jon E Walker; Rachel X Chen; Jeannine McGee; Catherine Nacey; Richard B Pollard; Mehrdad Abedi; Gerhard Bauer; Jan A Nolta; Joseph S Anderson
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

2.  Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy.

Authors:  Anjali Joshi; Himanshu Garg; Sherimay Ablan; Eric O Freed; Kunio Nagashima; N Manjunath; Premlata Shankar
Journal:  Virology       Date:  2011-05-06       Impact factor: 3.616

3.  Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.

Authors:  Joseph S Anderson; Jon Walker; Jan A Nolta; Gerhard Bauer
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

4.  Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.

Authors:  Joseph S Anderson; John Javien; Jan A Nolta; Gerhard Bauer
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

5.  Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification.

Authors:  Himanshu Garg; Anjali Joshi
Journal:  Hum Gene Ther       Date:  2016-03-30       Impact factor: 5.695

6.  HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector.

Authors:  Joseph Anderson; Ramesh Akkina
Journal:  AIDS Res Ther       Date:  2005-01-13       Impact factor: 2.250

7.  CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.

Authors:  Joseph Anderson; Ramesh Akkina
Journal:  Retrovirology       Date:  2005-08-18       Impact factor: 4.602

8.  Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor.

Authors:  Alexander Falkenhagen; Jastaranpreet Singh; Sabah Asad; Danila Leontyev; Stanley Read; Juan Carlos Zúñiga-Pflücker; Sadhna Joshi
Journal:  Mol Ther Nucleic Acids       Date:  2017-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.